Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 36kWORD 16k
11 May 2021
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: P-000388/2021

The EU Strategy for COVID-19 vaccines(1) was developed on the basis of a strong mandate from Member States, according to the principle that working together is the best way to provide enough vaccines for the European Union.

The Commission has secured a portfolio of more than 2.6 billion doses to date and announced that it would enter into a negotiation with BioNTech-Pfizer for a third contract for the delivery of 1.8 billion doses of vaccine over the period of 2021 to 2023.

The Commission considers that these supply lines will fully address the needs of the Member States.

Taking into account the principle of sincere cooperation and based on the spirit of the EU Strategy for COVID-19 vaccines, the Commission has always strongly encouraged Member States to express their need for additional doses to the Commission and the other Member States ensuring that related discussions take place transparently during Steering Board meetings and lead to a collective decision which can benefit all Member States.

Some Member States have also invested at national level in scaling up vaccines’ production. If so, they have concluded specific arrangements as a basis of public investments and/or specific national rules apply. However, this information has been, according to Commission’s knowledge, transparently brought to the attention of the Commission for being assessed, including in the light of applicable competition rules.

So far the Commission has not been informed of any breach of the obligation entered into by Member States not to negotiate separately with vaccines manufacturers which concluded (advance) purchase contract with the Commission.

Last updated: 11 May 2021Legal notice - Privacy policy